{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:38:51Z","timestamp":1790206731629,"version":"4.1.0"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T00:00:00Z","timestamp":1721174400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/ http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background and Aims:<\/jats:title>\n                    <jats:p>DILI frequently contributes to the attrition of new drug candidates and is a common cause for the withdrawal of approved drugs from the market. Although some noncytochrome P450 (non-CYP) metabolism enzymes have been implicated in DILI development, their association with DILI outcomes has not been systematically evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Approach and Results:<\/jats:title>\n                    <jats:p>\n                      In this study, we analyzed a large data set comprising 317 drugs and their interactions\n                      <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                      with 42 non-CYP enzymes as substrates, inducers, and\/or inhibitors retrieved from historical regulatory documents using multivariate logistic regression. We examined how these\n                      <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                      drug-enzyme interactions are correlated with the drugs\u2019 potential for DILI concern, as classified in the Liver Toxicity Knowledge Base database. Our study revealed that drugs that inhibit non-CYP enzymes are significantly associated with high DILI concern. Particularly, interaction with UDP-glucuronosyltransferases (UGT) enzymes is an important predictor of DILI outcomes. Further analysis indicated that only pure UGT inhibitors and dual substrate inhibitors, but not pure UGT substrates, are significantly associated with high DILI concern.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Drug interactions with UGT enzymes may independently predict DILI, and their combined use with the rule-of-two model further improves overall predictive performance. These findings could expand the currently available tools for assessing the potential for DILI in humans.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/hep.0000000000001007","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T14:06:56Z","timestamp":1721311616000},"page":"1512-1521","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":15,"title":["Drug interaction with UDP-Glucuronosyltransferase (UGT) enzymes is a predictor of drug-induced liver injury"],"prefix":"10.1097","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0391-5244","authenticated-orcid":false,"given":"AyoOluwa O.","family":"Olubamiwa","sequence":"first","affiliation":[{"name":"Division of Bioinformatics and Biostatistics, National Center for Toxicological Research (NCTR), U.S. Food and Drug Administration, Jefferson, Arkansas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-Jen","family":"Liao","sequence":"additional","affiliation":[{"name":"Division of Bioinformatics and Biostatistics, National Center for Toxicological Research (NCTR), U.S. Food and Drug Administration, Jefferson, Arkansas, USA"},{"name":"Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinwen","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Information Science, University of Arkansas at Little Rock, Arkansas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Dehanne","sequence":"additional","affiliation":[{"name":"Life Sciences, Elsevier B.V Radarweg, Amsterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Noban","sequence":"additional","affiliation":[{"name":"Life Sciences, Elsevier B.V Radarweg, Amsterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeliz","family":"Angin","sequence":"additional","affiliation":[{"name":"Life Sciences, Elsevier B.V Radarweg, Amsterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Barberan","sequence":"additional","affiliation":[{"name":"Life Sciences, Elsevier B.V Radarweg, Amsterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6453-2351","authenticated-orcid":false,"given":"Minjun","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Bioinformatics and Biostatistics, National Center for Toxicological Research (NCTR), U.S. Food and Drug Administration, Jefferson, Arkansas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,7,17]]},"reference":[{"key":"R1-20250520","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/clpt.2011.63","article-title":"Drug safety sciences and the bottleneck in drug development","volume":"89","author":"Watkins","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"R2-20250520","doi-asserted-by":"crossref","first-page":"947","DOI":"10.7326\/0003-4819-137-12-200212170-00007","article-title":"Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States","volume":"137","author":"Ostapowicz","year":"2002","journal-title":"Ann Intern Med"},{"key":"R3-20250520","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S0140-6736(19)31894-X","article-title":"Acute liver failure","volume":"394","author":"Stravitz","year":"2019","journal-title":"Lancet"},{"key":"R4-20250520","doi-asserted-by":"crossref","first-page":"11397","DOI":"10.1021\/acs.jmedchem.0c00524","article-title":"Drug induced liver lnjury (DILI). Mechanisms and medicinal chemistry avoidance\/mitigation strategies","volume":"63","author":"Norman","year":"2020","journal-title":"J Med Chem"},{"key":"R5-20250520","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12916-016-0553-2","article-title":"Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: A systematic review of the world literature","volume":"14","author":"Onakpoya","year":"2016","journal-title":"BMC Med"},{"key":"R6-20250520","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/hep.26208","article-title":"High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury","volume":"58","author":"Chen","year":"2013","journal-title":"Hepatology"},{"key":"R7-20250520","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1007\/s00204-019-02492-9","article-title":"Prediction of human drug-induced liver injury (DILI) in relation to oral doses and blood concentrations","volume":"93","author":"Albrecht","year":"2019","journal-title":"Arch Toxicol"},{"key":"R8-20250520","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41573-019-0048-x","article-title":"Managing the challenge of drug-induced liver injury a roadmap for the development and deployment of preclinical predictive models","volume":"19","author":"Weaver","year":"2020","journal-title":"Nature Reviews Drug Discovery"},{"key":"R9-20250520","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1002\/hep.27206","article-title":"Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump","volume":"60","author":"Aleo","year":"2014","journal-title":"Hepatology"},{"key":"R10-20250520","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/S0140-6736(00)03137-8","article-title":"Idiosyncratic drug reactions: The reactive metabolite syndromes","volume":"356","author":"Knowles","year":"2000","journal-title":"Lancet"},{"key":"R11-20250520","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1124\/dmd.113.056267","article-title":"High daily dose and being a substrate of cytochrome P450 enzymes are two important predictors of drug-induced liver injury","volume":"42","author":"Yu","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"R12-20250520","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/hep.28678","article-title":"A model to predict severity of drug-induced liver injury in humans","volume":"64","author":"Chen","year":"2016","journal-title":"Hepatology"},{"key":"R13-20250520","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/hep.23317","article-title":"Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events","volume":"51","author":"Lammert","year":"2010","journal-title":"Hepatology"},{"key":"R14-20250520","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.3390\/ijms22073441","article-title":"Idiosyncratic drug induced liver injury, cytochrome P450, metabolic risk factors and lipophilicity: Highlights and controversies","volume":"22","author":"Teschke","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R15-20250520","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.bbagen.2006.07.003","article-title":"Complex reactions catalyzed by cytochrome P450 enzymes","volume":"1770","author":"Isin","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"R16-20250520","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/jcph.23","article-title":"Drug-induced liver injury: The role of drug metabolism and transport","volume":"53","author":"Corsini","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"R17-20250520","doi-asserted-by":"crossref","first-page":"376","DOI":"10.5588\/ijtld.11.0404","article-title":"UGT1A1 polymorphisms associated with risk of induced liver disorders by anti-tuberculosis medications","volume":"16","author":"Chang","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"R18-20250520","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1124\/dmd.116.070763","article-title":"Prevalence of non\u2013cytochrome P450\u2013mediated metabolism in food and drug administration\u2013approved oral and intravenous drugs: 2006\u20132015","volume":"44","author":"Cerny","year":"2016","journal-title":"Drug Metabolism and Disposition"},{"key":"R19-20250520","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/03602532.2016.1225756","article-title":"Non-cytochrome P450-mediated bioactivation and its toxicological relevance","volume":"48","author":"Gan","year":"2016","journal-title":"Drug Metabolism Reviews"},{"key":"R20-20250520","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.drudis.2011.05.007","article-title":"FDA-approved drug labeling for the study of drug-induced liver injury","volume":"16","author":"Chen","year":"2011","journal-title":"Drug Discov Today"},{"key":"R27-20250520","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v028.i05","article-title":"Building predictive models in R using the caret package","volume":"28","author":"Kuhn","year":"2008","journal-title":"J Statist Softw"},{"key":"R28-20250520"},{"key":"R29-20250520","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/hep.26175","article-title":"LiverTox: A website on drug-induced liver injury","volume":"57","author":"Hoofnagle","year":"2013","journal-title":"Hepatology"},{"key":"R30-20250520","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.3390\/diagnostics11101754","article-title":"The LiverTox paradox-gaps between promised data and reality check","volume":"11","author":"Teschke","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"R31-20250520","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s40261-017-0572-6","article-title":"Genetic polymorphisms of SLCO1B1, CYP2E1 and UGT1A1 and susceptibility to anti-tuberculosis drug-induced hepatotoxicity: A Chinese population-based prospective case-control study","volume":"37","author":"Sun","year":"2017","journal-title":"Clin Drug Investig"},{"key":"R32-20250520","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1053\/j.gastro.2006.11.023","article-title":"Genetic susceptibility to diclofenac-induced hepatotoxicity: Contribution of UGT2B7, CYP2C8, and ABCC2 genotypes","volume":"132","author":"Daly","year":"2007","journal-title":"Gastroenterology"},{"key":"R33-20250520","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1081\/DMR-120000653","article-title":"The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism","volume":"33","author":"Fisher","year":"2001","journal-title":"Drug Metab Rev"},{"key":"R34-20250520","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.biocel.2013.02.019","article-title":"The UDP-glucuronosyltransferases: Their role in drug metabolism and detoxification","volume":"45","author":"Rowland","year":"2013","journal-title":"Int J Biochem Cell Biol"},{"key":"R35-20250520","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.drudis.2020.07.009","article-title":"Acyl glucuronide reactivity in perspective","volume":"25","author":"Bradshaw","year":"2020","journal-title":"Drug Discov Today"},{"key":"R36-20250520","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00007691-200302000-00001","article-title":"Acyl glucuronide drug metabolites: Toxicological and analytical implications","volume":"25","author":"Shipkova","year":"2003","journal-title":"Ther Drug Monit"},{"key":"R38-20250520","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1086\/313680","article-title":"Trovafloxacin-induced acute hepatitis","volume":"30","author":"Lucena","year":"2000","journal-title":"Clinical Infectious Diseases"},{"key":"R39-20250520","doi-asserted-by":"crossref","first-page":"105533","DOI":"10.1016\/j.tiv.2022.105533","article-title":"Novel insights into bile acid detoxification via CYP, UGT and SULT enzymes","volume":"87","author":"Kastrinou Lampou","year":"2023","journal-title":"Toxicology in Vitro"},{"key":"R40-20250520","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1124\/dmd.31.1.133","article-title":"Validation of Serotonin (5-Hydroxtryptamine) as an in vitro substrate probe for human UDP-glucuronosyltransferase (UGT) 1A6","volume":"31","author":"Krishnaswamy","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"R41-20250520","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0960-0760(99)00061-8","article-title":"Characterization of UDP-glucuronosyltransferases active on steroid hormones","volume":"69","author":"Hum","year":"1999","journal-title":"The J Steroid Biochem Mol Biol"},{"key":"R42-20250520","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.bcp.2015.04.020","article-title":"Roles of human UDP-glucuronosyltransferases in clearance and homeostasis of endogenous substrates, and functional implications","volume":"96","author":"Bock","year":"2015","journal-title":"Biochem Pharmacol"},{"key":"R43-20250520","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1194\/jlr.M300010-JLR200","article-title":"Glucuronidation of arachidonic and linoleic acid metabolites by human UDP-glucuronosyltransferases","volume":"44","author":"Turgeon","year":"2003","journal-title":"J Lipid Res"},{"key":"R44-20250520","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1046\/j.1440-1746.1999.01984.x","article-title":"Molecular genetic basis of Gilbert\u2019s syndrome","volume":"14","author":"Burchell","year":"1999","journal-title":"J Gastroenterol Hepatol"},{"key":"R45-20250520","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1172\/JCI117008","article-title":"Identification of two single base substitutions in the UGT1 gene locus which abolish bilirubin uridine diphosphate glucuronosyltransferase activity in vitro","volume":"93","author":"Erps","year":"1994","journal-title":"J Clin Invest"},{"key":"R46-20250520","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0168-8278(02)00359-8","article-title":"Inherited disorders of bilirubin metabolism","volume":"38","author":"Bosma","year":"2003","journal-title":"J Hepatol"},{"key":"R48-20250520","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/BF01296041","article-title":"Carbamazepine-induced acute cholangitis","volume":"32","author":"Larrey","year":"1987","journal-title":"Dig Dis Sci"},{"key":"R49-20250520","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/ncpgasthep0871","article-title":"Drug-induced acute cholestatic liver damage in a patient with mutation of UGT1A1","volume":"4","author":"Rigato","year":"2007","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"key":"R50-20250520","doi-asserted-by":"crossref","first-page":"1700127","DOI":"10.1002\/minf.201700127","article-title":"Classifiers and their metrics quantified","volume":"37","author":"Brown","year":"2018","journal-title":"Mol Inform"},{"key":"R51-20250520","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12864-019-6413-7","article-title":"The advantages of the Matthews correlation coefficient (MCC) over F1 score and accuracy in binary classification evaluation","volume":"21","author":"Chicco","year":"2020","journal-title":"BMC Genomics"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/HEP.0000000000001007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T17:00:16Z","timestamp":1747760416000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/HEP.0000000000001007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,17]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/hep.0000000000001007","relation":{},"ISSN":["0270-9139","1527-3350"],"issn-type":[{"value":"0270-9139","type":"print"},{"value":"1527-3350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,17]]},"assertion":[{"value":"2024-03-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}